https://doi.org/10.4081/hmr.v1i8.281

CD30: a suitable target for immunotherapy?

Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
Published: May 29, 2009
Abstract Views: 155
PDF: 453
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Paola Borchmann
support@pagepress.org
The CD30 antigen and its physiological function CD30 is a 120 kDa transmembrane glycoprotein belonging to the TNF-receptor superfamily and lacking an intracellular death domain. Physiologically, expression of CD30 is found on virus-infected lymphocytes and on a small subset of activated T cells. Furthermore this receptor is involved in the negative selection process of auto-reactive lymphocytes.1 The CD30 ligand (CD30L) is present on activated T cells, resting B cells, and granulocytes. As shown for most other members of the TNF-receptor family signaling via CD30 is pleiotropic and may result in different responses including apoptosis, differentiation and growth stimulation even in monoclonal cells. This response may depend on the developmental status and environment of the cell.2

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Borchmann, P. (2009). CD30: a suitable target for immunotherapy?. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.281
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).